Opportunity ID: 307522

General Information

Document Type: Grants Notice
Funding Opportunity Number: RFA-AI-18-029
Funding Opportunity Title: HIV Drug Resistance: Genotype-Phenotype-Outcome Correlations (R01 Clinical Trial Not Allowed)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Grant
Category of Funding Activity: Health
Category Explanation:
Expected Number of Awards:
Assistance Listings: 93.855 — Allergy and Infectious Diseases Research
Cost Sharing or Matching Requirement: No
Version: Synopsis 1
Posted Date: Jul 24, 2018
Last Updated Date:
Original Closing Date for Applications: Dec 05, 2018
Current Closing Date for Applications: Dec 05, 2018
Archive Date: Jan 10, 2019
Estimated Total Program Funding:
Award Ceiling: $500,000
Award Floor:

Eligibility

Eligible Applicants: City or township governments
Special district governments
County governments
Native American tribal organizations (other than Federally recognized tribal governments)
Small businesses
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
State governments
For profit organizations other than small businesses
Private institutions of higher education
Public and State controlled institutions of higher education
Native American tribal governments (Federally recognized)
Public housing authorities/Indian housing authorities
Independent school districts
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Additional Information

Agency Name: National Institutes of Health
Description: The purpose of this Funding Opportunity Announcement is to support studies that will evaluate HIV drug resistance and its relationship to treatment success. Applications are sought proposing studies of genotype/phenotype correlations in diverse subtypes, the relationship between drug resistance mutations present in minority variant viral populations and treatment outcomes, and on the reasons for the discordance between genotype and treatment success or failure. Laboratory evaluations of samples with clinical correlates in patients on recommended regimens are encouraged.
Link to Additional Information: http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-18-029.html
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV

Email:FBOWebmaster@OD.NIH.GOV

Version History

Version Modification Description Updated Date

Related Documents

Packages

Agency Contact Information: NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV

Email: FBOWebmaster@OD.NIH.GOV

Who Can Apply: Organization Applicants

Assistance Listing Number Competition ID Competition Title Opportunity Package ID Opening Date Closing Date Actions
FORMS-E FORMS-E PKG00243969 Nov 05, 2018 Dec 05, 2018 View

Package 1

Mandatory forms

307522 RR_SF424_2_0-2.0.pdf

307522 PHS398_CoverPageSupplement_4_0-4.0.pdf

307522 RR_OtherProjectInfo_1_4-1.4.pdf

307522 PerformanceSite_2_0-2.0.pdf

307522 RR_KeyPersonExpanded_2_0-2.0.pdf

307522 PHS398_ResearchPlan_4_0-4.0.pdf

Optional forms

307522 RR_Budget_1_4-1.4.pdf

307522 RR_SubawardBudget30_1_4-1.4.pdf

307522 PHS398_ModularBudget_1_2-1.2.pdf

307522 PHS_AssignmentRequestForm_2_0-2.0.pdf

2025-07-09T18:19:57-05:00

Share This Post, Choose Your Platform!

About the Author: